Climb Bio, Inc. CLYM Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $8.36M-76.6% | $35.69M+38.3% | $25.8M+13.8% | $22.68M-21.8% | $29.02M-66.7% | ||
| $101.21M+54.8% | $65.4M+7.0% | $61.1M-1.5% | $62.02M-10.2% | $69.04M+8.4% | ||
| $3.84M-19.5% | $4.77M+17.4% | $4.06M+51.5% | $2.68M+20.9% | $2.22M-43.9% | ||
| $113.4M+7.1% | $105.85M+16.4% | $90.96M+4.1% | $87.38M-12.9% | $100.28M-35.2% | ||
| $250K-13.2% | $288K-9.4% | $318K+1.3% | $314K— | —— | ||
| $447K-11.5% | $505K-10.1% | $562K-9.1% | $618K+37.0% | $451K-8.0% | ||
| $1.53M0.0% | $1.53M0.0% | $1.53M+11.8% | $1.37M+505% | $226K+1,313% | ||
| $152.37M-9.2% | $167.74M-8.0% | $182.3M-5.2% | $192.39M-4.2% | $200.74M-7.6% | ||
| $860K-62.1% | $2.27M+376% | $477K-49.6% | $946K+21.8% | $777K+10.2% | ||
| $2.95M-33.9% | $4.46M+5.1% | $4.24M-15.7% | $5.04M-17.5% | $6.1M+50.0% | ||
| $263K+2.7% | $256K+12.3% | $228K+2.7% | $222K+43.2% | $155K-1.3% | ||
| $4.07M-41.7% | $6.98M+41.1% | $4.95M-20.2% | $6.21M-11.8% | $7.04M+42.7% | ||
| $216K-24.2% | $285K-19.0% | $352K-15.6% | $417K+30.7% | $319K-14.9% | ||
| $4.29M-41.0% | $7.27M+37.1% | $5.3M-19.9% | $6.62M-10.0% | $7.36M+38.6% | ||
| $5K0.0% | $5K-28.6% | $7K0.0% | $7K0.0% | $7K0.0% | ||
| $451.37M+0.4% | $449.76M+0.2% | $448.74M+0.9% | $444.76M+0.2% | $443.75M+0.5% | ||
| -$303.45M-4.7% | -$289.73M-6.4% | -$272.21M-5.0% | -$259.32M-3.5% | -$250.66M-9.0% | ||
| $157K-63.9% | $435K-7.2% | $469K+47.5% | $318K+11.2% | $286K+1,143% | ||
| $148.09M-7.7% | $160.48M-9.3% | $177M-4.7% | $185.76M-3.9% | $193.39M-8.7% | ||
| $152.37M-9.2% | $167.74M-8.0% | $182.3M-5.2% | $192.39M-4.2% | $200.74M-7.6% | ||
| $101.21M+54.8% | $65.4M+7.0% | $61.1M-1.5% | $62.02M-10.2% | $69.04M+8.4% | ||
| $1.53M0.0% | $1.53M0.0% | $1.53M+11.8% | $1.37M+505% | $226K+1,313% | ||
| $447K-11.5% | $505K-10.1% | $562K-9.1% | $618K+37.0% | $451K-8.0% | ||
| $447K-11.5% | $505K-10.1% | $562K-9.1% | $618K+37.0% | $451K-8.0% | ||
| $1.53M0.0% | $1.53M0.0% | $1.53M+11.8% | $1.37M+505% | $226K+1,313% | ||
| $447K-11.5% | $505K-10.1% | $562K-9.1% | $618K+37.0% | $451K-8.0% | ||
| $1.53M0.0% | $1.53M0.0% | $1.53M+11.8% | $1.37M+505% | $226K+1,313% | ||
| $2.95M-33.9% | $4.46M+5.1% | $4.24M-15.7% | $5.04M— | —— | ||
| $479K-11.5% | $541K-6.7% | $580K-9.2% | $639K+34.8% | $474K-10.9% | ||
| $451.37M+0.4% | $449.76M+0.2% | $448.74M+0.9% | $444.76M+0.2% | $443.75M+0.5% | ||
| $5K0.0% | $5K-28.6% | $7K0.0% | $7K0.0% | $7K0.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Climb Bio, Inc.'s total assets?
- Climb Bio, Inc. (CLYM) holds $152.4M in total assets, down 24.1% year over year.
- How much debt does Climb Bio, Inc. have?
- Climb Bio, Inc. carries $479.0K in total debt against $148.1M of shareholders' equity, a debt-to-equity ratio of 0.00.
- How much cash does Climb Bio, Inc. have?
- Climb Bio, Inc. holds $8.4M in cash and equivalents.
- Can Climb Bio, Inc. cover its short-term obligations?
- Its current ratio is 27.86 — current assets exceed current liabilities.
- Where does Climb Bio, Inc.'s balance sheet data come from?
- Every line is extracted from Climb Bio, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.